November 19, 2019
Takeda Pharmaceutical aims to win approval for 12 new molecular entities (NMEs) through FY2024, with CEO Christophe Weber “convinced” that revenue growth from these, coupled with its current 14 global brands, will be “sufficient to offset the headwinds” of looming...read more